Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Harvard College

Instituto Carlos Slim De La Salud, A.c.

William C Hahn

Stuart L Schreiber

Lee M Nadler

Jean Zhao

Partha Pratim Nag

Pablo Tamayo

Laura Corral

Thomas M Roberts

David E Root

Jesse S Boehm

Joseph Rosenbluh

Joachim L Schultze

Cigall Kadoch

Aviad Tsherniak

Jill P Mesirov

David Root

Robert H Vonderheide

David E Hill

Andrew J Aguirre

Robin M Meyers

Gabriel Sandoval

April Cook

Glenn Cowley

Barbara Weir

Francisca Vazquez

Srivatsan Raghavan

Anna A Sablina

Shubhroz Gill

Paul Clemons

Raymond Ng

Bruce Kuan-Yee Hua

Andrew Aguirre

Robin Meyers

Aviad Tshermiak

Colles Price

The present invention provides methods of screening for compounds that interfere with the interaction between ERG. ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins. Included are methods of screening for compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and BAF155. Methods of treating prostate cancer with compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins are also provided.

Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers

Provided herein are compounds useful for the treatment of various proliferative diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compositions, and may be used in methods of treatment and/or prophylaxis of proliferative diseases, including cancer, and more specifically, pancreatic cancer.

Cyclopentaimidazolones for the treatment of cancer

The present invention provides methods of treating a subject having a Wnt/beta-catenin active cancer by administering to said subject a compound that inhibits the expression or activity of YES1, BIRC5 or BCL2L1, a compound that inhibits YAP1-beta-catenin complex formation, a compound that inhibits YAP1-beta-catenin complex binding to DNA, a compound that inhibits YAP1-beta-catenin-TBX5 complex formation, or any combination thereof. The compound can be, for example, a nucleic acid, a peptide, an antibody or a small molecule. Methods of screening for therapeutic targets for treating cancer are included.

Methods of treating cancer having an active Wnt/β-catenin pathway

The present invention relates to compositions and methods for targeting cancer-specific DNA sequences, such as copy number amplifications and other types of cancer-specific sequence variations, such as cancer-specific polymorphisms, insertions, or deletions. The present invention provides hereto sequence-specific DNA targeting agents targeting a sequence within the amplified DNA region or a sequence otherwise specific for a cancer cell compared to a non-cancer cell. The invention further relates to methods for treating cancer, comprising administering such sequence-specific DNA targeting agents. The invention further relates to methods for preparing sequence-specific DNA targeting agent, as well as screening methods using the DNA targeting agents.

Compositions and methods for targeting cancer-specific sequence variations

Methods of treating cancer having an active Wnt/&#x3b2;-catenin pathway

The present invention provides methods of detecting cancer using biomarkers.

Signatures and determinants associated with cancer and methods of use thereof

Antibodies that are specific for human Ra1A that is phosphorylated at one or both of Ser183 and Ser194 are described as various methods such antibodies, including diagnostic methods and screening methods.

Phosphorylated RaIA

Provided herein are nucleic acids, proteins, vectors, cells, kits, devices and methods useful for identifying regulatable proteins that are able to complement components of cellular signaling pathways. Also provided are compositions and methods using these complementing genes directly as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics. Further provided are methods for using changes caused by expression of the complementing genes to indirectly identify associated genes to be used as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics.

Compositions and methods for identifying transforming and tumor suppressor genes

The invention provides methods for conducting cancer immunotherapy and diagnosis using universal tumor associated antigens, such as the telomerase catalytic subunit (hTERT), and methods for identifying and characterizing universal tumor associated antigens.

Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERT

Growing community of inventors

Newton, MA, United States of America

William C Hahn